Cellworks Group Inc., a leader in personalized therapy decision support and precision drug development, recently announced the results of a study demonstrating the accuracy of its biosimulation platform in predicting…
Inflammasome Therapeutics, a private company, has finished enrolling participants in a Phase I pharmacokinetics and safety study for its novel drug K9. This brain- and retina-penetrant compound is being evaluated…
Oisín Biotechnologies, a private biotech firm focused on combating age-related diseases, announced the publication of preclinical data from its follistatin (FST) gene therapy program aimed at reducing muscle loss. The…
An exploratory analysis of the TROPION-Lung01 Phase III trial found that the TROP2 biomarker, assessed via AstraZeneca’s computational pathology platform, Quantitative Continuous Scoring (QCS), effectively predicted clinical outcomes in patients…
Sensorion (FR0012596468 – ALSEN), a leading clinical-stage biotechnology company focused on innovative therapies for hearing loss, has announced its participation in the 36th World Congress of Audiology (WCA) in Paris…
Daiichi Sankyo Europe today reaffirmed its dedication to tackling unmet needs and barriers in cardiovascular care by highlighting treatment disparities and outcomes among different patient groups. This announcement coincides with…
CharmHealth, a leader in healthcare technology solutions, has unveiled the winners of its 2024 Innovation Challenge. Entering its fourth year, the challenge aims to discover groundbreaking ideas poised to transform…
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, has announced detailed results from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic for the treatment of…
BostonGene, a leader in AI-driven molecular and immune profiling, will showcase its advanced technologies at the 14th World Clinical Biomarkers & CDx Summit 2024, held from September 3 – 6…
Delcath Systems, Inc. (Nasdaq: DCTH), a company specializing in interventional oncology for treating liver cancers, announced the publication of a clinical study in the journal Therapeutic Advances in Medical Oncology.…
Navigator Medicines, a biotech company focused on advancing biologics for immune regulation, announced a $100 million Series A financing and the in-licensing of NAV-240 and an OX40L-targeted portfolio from IMBiologics…
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company dedicated to developing and commercializing seralutinib for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), has…